Sofinnova Partners, a prominent European venture capital firm, has successfully closed its latest fund, Sofinnova Capital XI, at €650 million ($750 million). This amount significantly surpasses the firm’s initial target, highlighting strong investor confidence in early-stage healthcare opportunities. The announcement was made on November 16, 2025, marking a noteworthy achievement for the Paris-based firm.
The new fund aims to support innovative healthcare companies, particularly those in the early stages of development. With a focus on biotechnology, medical devices, and digital health, Sofinnova Capital XI is poised to identify and nurture promising projects that can transform patient care and medical outcomes.
Strong Investor Demand Drives Fund Success
Sofinnova Partners has established itself as a leader in life sciences investment across Europe. The firm’s ability to exceed its fundraising target reflects the growing interest in the healthcare sector, especially in light of recent global health challenges. Investors are increasingly seeking opportunities in companies that are addressing critical healthcare needs through cutting-edge technology and research.
With offices in Paris, London, and Milan, Sofinnova is strategically positioned to tap into diverse markets and foster cross-border collaborations. The firm has a strong track record of nurturing start-ups and guiding them through pivotal stages of growth, making it a sought-after partner for innovative healthcare entrepreneurs.
The closing of Sofinnova Capital XI comes at a time when investment in healthcare is vital. As the world continues to recover from the impacts of the COVID-19 pandemic, there is an urgent need for advancements in medical technology and care solutions.
Commitment to Innovation and Growth
Sofinnova Partners is committed to supporting companies that are not only commercially viable but also address significant health issues. The firm’s investment strategy emphasizes long-term growth and sustainability, ensuring that the companies it backs are equipped to make meaningful contributions to healthcare.
In a statement, the firm expressed enthusiasm about the prospects that Sofinnova Capital XI will bring. The fund is expected to make significant investments in early-stage companies over the coming years, contributing to the evolution of healthcare and enhancing the quality of life for patients worldwide.
As healthcare continues to evolve, Sofinnova Partners remains at the forefront, leveraging its expertise and resources to foster innovation. The closing of Sofinnova Capital XI marks a critical step in the firm’s mission to drive positive change in the healthcare landscape, ensuring that it remains a key player in the global venture capital ecosystem.
